Hahn Chang-Gyu, Wang Hoau-Yan, Koneru Ramesh, Levinson Douglas F, Friedman Eitan
Medical College of Pennsylvania, Philadelphia, PA, USA.
J Psychiatr Res. 2005 Jul;39(4):355-63. doi: 10.1016/j.jpsychires.2004.10.007.
Dysregulated protein kinase C (PKC) distribution and activation, and abnormal receptor-G protein coupling, have been implicated in the pathophysiology of bipolar affective disorder (BD). The therapeutic effectiveness of lithium has also been correlated with its ability to reduce PKC activation and G protein-mediated signaling. We examine the cellular distribution and activation of PKC and receptor-G protein coupling in blood platelets from normal controls, patients with BD mania or schizophrenia during treatment-free state, and after lithium or valproic acid administration. PKC activity was measured under basal and 50 nM phorbol 12-myristate, 13-acetate (PMA), 1 microM serotonin or 0.5 U/ml thrombin-stimulated conditions. The coupling of G proteins to serotonin or thrombin receptors were assessed by serotonin or thrombin-mediated [35S]GTPgammaS binding to membrane Galpha proteins. The results demonstrate that membrane-associated PKC activity and stimulus-induced PKC translocation are increased in BD manic, whereas stimulus-elicited PKC translocation is attenuated in schizophrenic patients. Lithium and valproic acid treatments attenuated the stimulus-induced PKC translocations to a similar degree and decreased PKC activity in both cytosolic and membranous fractions after two weeks of drug administration. An increase in 5-HT or thrombin stimulated [35S]GTPgammaS binding to Galpha proteins was detected in BD manic but not in schizophrenic patients although basal [35S]GTPgammaS binding was not different across the diagnostic groups. Lithium and valproic acid treatments similarly reduced receptor-G protein coupling with comparable time courses. Thus, increased membrane-associated PKC, cytosol to membrane PKC translocation and receptor-G protein coupling in platelets of BD manic patients were alleviated by lithium or valproic acid treatments.
蛋白激酶C(PKC)分布和激活失调,以及受体 - G蛋白偶联异常,与双相情感障碍(BD)的病理生理学有关。锂的治疗效果也与其降低PKC激活和G蛋白介导信号传导的能力相关。我们研究了正常对照、处于未治疗状态的BD躁狂症患者或精神分裂症患者以及服用锂或丙戊酸后的血小板中PKC的细胞分布和激活情况,以及受体 - G蛋白偶联情况。在基础条件以及50 nM佛波酯12 - 肉豆蔻酸酯13 - 乙酸酯(PMA)、1 μM血清素或0.5 U/ml凝血酶刺激条件下测量PKC活性。通过血清素或凝血酶介导的[35S]GTPγS与膜Gα蛋白的结合来评估G蛋白与血清素或凝血酶受体的偶联情况。结果表明,BD躁狂症患者的膜相关PKC活性和刺激诱导的PKC易位增加,而精神分裂症患者刺激引发的PKC易位减弱。锂和丙戊酸治疗在给药两周后,以相似程度减弱刺激诱导的PKC易位,并降低胞质和膜部分的PKC活性。在BD躁狂症患者中检测到5 - HT或凝血酶刺激的[35S]GTPγS与Gα蛋白的结合增加,但在精神分裂症患者中未检测到,尽管各诊断组的基础[35S]GTPγS结合无差异。锂和丙戊酸治疗同样在相似的时间进程中降低受体 - G蛋白偶联。因此,锂或丙戊酸治疗可缓解BD躁狂症患者血小板中增加的膜相关PKC、胞质到膜的PKC易位以及受体 - G蛋白偶联。